Neo Comprehensive - Myeloid Disorders
Use
The Neo Comprehensive - Myeloid Disorders assay detects relevant aberrations for the purpose of diagnostic evaluation, prognosis, risk stratification, and therapy guidance. It covers a wide spectrum of myeloid neoplasms, including acute myeloid leukemia (AML); chronic myeloid leukemia (CML); chronic myelomonocytic leukemia (CMML); myelodysplastic neoplasms (MDS); myeloproliferative neoplasms (MPN), e.g., polycythemia vera (PV), primary myelofibrosis (PMF), and essential thrombocythemia (ET); myeloid neoplasms with eosinophilia and defining gene rearrangement; histiocytic neoplasms, such as Langerhans cell histiocytosis (LCH) or Erdheim-Chester Disease (ECD); mastocytosis; myeloid precursor lesions.
Special Instructions
FLT3 by PCR (via FLT3 Mutation Analysis) is available as Client‑Bill only when ordered concurrently with the Neo Comprehensive Myeloid Disorders assay. This result is reported separately from the Neo Comprehensive profile to support prompt therapy selection for patients with a new diagnosis of AML.
Limitations
Highly acidic or prolonged decalcification processes will not yield sufficient nucleic acid to accurately perform molecular studies. Mercury fixatives (B5) should not be used as they will not provide sufficient nucleic acid. Test is TNA-based. Please select Extract & Hold - TNA if specimen hold service is desired.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
2-3 mL
Minimum Volume
Not provided
Container
EDTA tube. Sodium heparin is acceptable.
Storage Instructions
Use cold pack for transport, ensuring it is not in direct contact with the specimen. Ship same day as drawn whenever possible.
Causes for Rejection
Highly acidic or prolonged decalcification processes will not yield sufficient nucleic acid.